Manufacturers Back Innovation Initiatives - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturers Back Innovation Initiatives
New legislation, government programs aim to bolster drug discovery and reduce regulatory hurdles.


Pharmaceutical Technology
Volume 36, Issue 6, pp. 26-29

Ensuring safety

Hamburg expressed concern that the strong "anti-government and anti-regulation sentiment" expressed in some legislative proposals could "lower FDA's high public health standards that have served patients, consumers, industry, and the public health for so long, and so well." High standards for safety and efficacy, she said, "will ensure that innovations actually help patients," and that they receive coverage from third-party payers.

FDA moved to highlight its increased commitment to drug safety over the last five years in a report from the Center for Drug Evaluation and Research (CDER) on "Advances in FDA's Safety Program for Marketed Drugs." CDER now spends equal resources on postmarket oversight as on premarket approval, reported Director Janet Woodcock, and new authorities provided by the FDA Amendments Act of 2007 have enabled the agency to require more than 385 postmarket drug safety studies, to mandate 65 new safety labeling changes, and to initiate 64 risk evaluation and mitigation strategies (REMS) since 2008.

However, a report from the Institute of Medicine on "Ethical and Scientific Issues in Studying the Safety of Approved Drugs" calls for FDA to do more to monitor and disclose safety issues involving marketed medicines. The expert panel, which launched this study in 2010 to help FDA prevent future Vioxx-type safety crises, advised the agency to create a comprehensive, publicly available document that would map drug risks and safety concerns throughout the product lifecycle. CDER officials dismissed that idea, noting that developing such a Benefit and Risk Assessment and Management Plan, or BRAMP, for every approved drug would be "challenging" given the agency's limited resources and probably would require lengthy new rulemaking.

Going global

What FDA would like to see in the PDUFA legislation is enhanced authority to ensure the safety and quality of drugs and active ingredients now imported from all over the world, as described in its new report on "Global Engagement" and last year's "Pathway to Global Product Safety and Quality." These documents note FDA's increased overseas presence through its network of international offices, as well as efforts to strengthen regulatory agencies in other countries, to collaborate on science-based standards, to share knowledge and inspection resources, and to develop a range of joint surveillance and preparedness activities.

At the FDLI meeting, Hamburg cited several legislative provisions that would enable the agency to deal with rising global drug production: make it easier for FDA to share confidential information with trusted regulatory authorities; enable FDA to refuse admission and to destroy unsafe drug imports; require manufacturers to report to FDA threats to the supply chain; and require a "robust" system to track and trace drugs throughout the supply chain.

The proposed generic-drug user-fee program, she noted, will help by supporting more frequent inspections of foreign manufacturers of active ingredient and drug products. There seems to be agreement that manufacturers should report earlier to FDA about looming shortage situations. But industry appears wary of legislation that sets stiff penalties for a host of reporting and disclosure requirements. Manufacturers don't want to invest millions in a system able to track drugs down to individual vials. The debate continues.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here